INVO Bioscience, Inc.: management transactions · United States · SEC (Form 4)

About INVO Bioscience, Inc.

INVO Bioscience, Inc. (NASDAQ: INVO) is a U.S.-based healthcare company focused on fertility services and technologies. Historically headquartered in Sarasota, Florida, the company was founded in January 2007 as Bio X Cell, Inc. to acquire assets tied to the INVOcell technology, which originated from Medelle Corporation. Over time, INVO evolved from a device-centric business into a broader fertility platform that combines proprietary technology with clinic operations. For investors, this makes INVO a specialized small-cap healthcare story with exposure to both medical-device commercialization and fertility-center economics. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1417926/000118518518002217/invobio20181219_s1.htm?utm_source=openai)) The company’s core business is built around two complementary pillars. First, INVO markets INVOcell, a medical device used for intravaginal culture (IVC) of embryos, positioned as a lower-cost, patient-friendly alternative in parts of the IVF process. Second, INVO has expanded into operating fertility clinics, including INVO Centers and IVF clinics, allowing it to participate directly in treatment delivery and recurring clinic revenue. INVO also distributes INVOcell through independently owned fertility clinics, which broadens the commercial reach of the product beyond its own facilities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1417926/000149315224012002/form424b5.htm?utm_source=openai)) From a competitive standpoint, INVO occupies a niche position in the fertility market. Its differentiation lies in pairing a proprietary device with clinic ownership, a model that can create multiple revenue streams and stronger control over the patient journey. At the same time, the business remains exposed to execution risk, reimbursement dynamics, regulatory requirements, and the operational complexity of running fertility clinics. As a U.S.-listed company on the NASDAQ, INVO benefits from market visibility, but it competes in a fragmented field where larger fertility networks and better-capitalized healthcare groups may have greater scale and purchasing power. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1417926/000149315224012002/form424b5.htm?utm_source=openai)) Recent corporate developments are important for understanding the current investment case. In 2024, INVO reported strong revenue growth and improving Adjusted EBITDA, supported by its clinical operations. It also stated that reported clinic revenue came from its Atlanta, Georgia INVO Center and its Madison, Wisconsin IVF clinic. Later in 2024, the company closed a merger with NAYA Biosciences, underscoring a significant period of corporate restructuring and strategic repositioning. For French-speaking investors, INVO is best viewed as a U.S. NASDAQ-listed fertility platform with a proprietary device angle, early-stage scaling potential, and a higher-risk profile typical of small-cap healthcare names. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1417926/000149315224019958/ex99-1.htm?utm_source=openai))